By Fineline Cube 
Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first‑half 2026 revenue of RMB 302 million, up 29% year‑on‑year, driven primarily by higher product sales revenue, which climbed 32.6% to RMB 282 million. The results underscore strengthening self‑sustaining cash generation from the company’s two commercial products, Olverembatinib and Lisaftoclax, alongside accelerating global expansion milestones.
1H 2026 Financial Highlights
| Item | 1H 2026 | YoY Change |
|---|---|---|
| Total Revenue | RMB 302 million | +29% |
| Product Sales Revenue | RMB 282 million | +32.6% |
| Commercial Products | Olverembatinib, Lisaftoclax | Dual‑engine growth drivers |
Dual‑Engine Commercial Momentum
- Olverembatinib and Lisaftoclax continue to drive product sales, strengthening the company’s self‑sustaining cash‑generation capabilities.
- Positive data disclosures from multiple pipeline assets validated the long‑term potential of the portfolio.
- Several global registrational Phase III trials are advancing rapidly, expanding the path toward additional approvals.
Corporate & Globalization Milestones
- “B” Removal Completed: Ascentage successfully removed the “B” designation from its Hong Kong Stock Exchange listing during the period — a marker of sustained commercial substance under HKEX rules.
- International Buildout: Expansion of the international team and acceleration of the overseas commercial layout proceeded across the board.
Global Collaborations & Research Partnerships
| Category | Partners |
|---|---|
| Biopharma Collaborations | Takeda, AstraZeneca, Merck & Co., Inc., Pfizer, Innovent |
| Academic R&D Partnerships | Dana‑Farber Cancer Institute, Mayo Clinic, U.S. National Cancer Institute, University of Michigan |
Ascentage has established a global intellectual property portfolio underpinning these collaborations, reinforcing its positioning among leading biopharmaceutical companies worldwide.
Market Impact & Outlook
- Commercial Inflection: With revenue up 29% and product sales growing 32.6%, Ascentage is transitioning from pipeline story to sustainable commercial operator.
- Pipeline De‑Risking: Positive readouts and advancing global Phase III registrational trials strengthen the case for future launches across the portfolio.
- Global Credibility: The “B” removal, expanding international team, and blue‑chip partnership roster — spanning Takeda, AstraZeneca, Merck, and Pfizer — bolster the company’s profile with global investors and partners.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Ascentage Pharma’s revenue trajectory, clinical development, and commercial expansion. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, market adoption, and competitive dynamics.-Fineline Info & Tech